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  Abstract 
 ABO-incompatible living-donor lobar lung transplantation was performed in a 10-year-old boy with 
bronchiolitis obliterans (BO) after bone marrow transplantation (BMT) for recurrent acute myeloid 
leukemia (AML). His blood type had changed from AB to O since he received BMT and he had no anti-
A/B antibody, and received type B and AB donor lobar lungs. To our knowledge, this case represents the 
first successful living-donor lobar lung transplantation from ABO-incompatible donors. 
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Introduction  
 ABO-incompatible organ transplantation, especially kidney and liver transplantation have been 
performed to overcome donor organ shortage.  However, very few cases have been reported involving 
ABO-incompatible lung transplantation, and furthermore, an intentional lung transplant has been reported 
only one case. Herein, we report ABO-incompatible lung transplantation in a 10-year-old boy with 
bronchiolitis obliterans (BO) after bone marrow transplantation (BMT). 
 
Case Report 
A 6-year-old boy was diagnosed with AML in 2005 and was treated with chemotherapy. In May 2008, 
at the age of 9, he underwent BMT from an unrelated, HLA-identical and ABO-mismatched donor for 
recurrent AML. His blood type was originally AB (+) and after receiving BMT from blood type O (+) 
donor, his blood type changed to O (+). In early 2009, at the age of 9, he began complaining of dyspnea 
and was diagnosed as having bronchiolitis obliterans, with the presumption that the cause was pulmonary 
GVHD. Respiratory distress continued to deteriorate with respiratory Pseudomonous Aeruginosa 
infection despite home oxygen therapy. 
In January 2010, at the age of 10, the patient was transferred to Kyoto University Hospital. On 
admission, his vital capacity was 0.72 L (39.6% predicted), FEV1 was 0.27L (16.3% predicted), and 
arterial blood gas demonstrated a pH of 7.40, PaO2 of 87.0 mmHg, and PaCO2 of 55.8 mmHg with 
2L/min oxygen administered via a nasal cannula. 
Cadaveric lung transplantation was not a realistic option because brain death is accepted only for 
persons over than 15 years old in Japan. His parents, mother, 43 years old, ABO type AB (+) and father, 
44 years old, ABO type B (+) each offered to be lung donors. The patient’s ABO type had changed to 
type O according to ABO testing of red cells, but ABO serum test did not detect any anti-A/B antibody in 
his serum and tolerance to A and B antigens had been established. After carefully discussion, we thought 
that the risk of ABO-incompatible lung transplant in this particular case would be equivalent to ABO-
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compatible transplant since the production of anti-A and anti B antibody would be unlikely even if new A 
and B antigen was presented from donor after lung transplantation. 
In February 2010, he underwent living-donor lobar lung transplantation with a left lower lobe from his 
mother and a right lower lobe from his father. The surgical aspects of the donor lobectomy, donor back 
table preservation technique, and recipient bilateral pneumonectomy and lobar implantation have been 
previously described by Starnes’ group 1. For perioperative transfusion, type O red blood cells and type 
AB fresh frozen plasma and platelets were used for the recipients. Postoperative immunosuppression 
included cyclosporine, mycophenolate mofetil, and prednisone. 
The postoperative course was relatively uneventful. The patient was completely weaned from the 
ventilator on postoperative day (POD) 3. There was transient very weak detection of anti-A antibody 
(Table 1). However, there was no apparent acute cellular rejection (ACR) or antibody-mediated rejection 
(AMR) postoperatively. Since there is no clinical finding suggesting rejection, No lung biopsy was 
performed postoperatively. 
 He was discharged from the hospital on POD 75. At that time, arterial blood gas in room air 
demonstrated a pH of 7.43, PaO2 of 92.6 mmHg, and PaCO2 of 37.6 mmHg. FVC was 1.53 L (83.2% 
predicted) and FEV1 was 1.12 L (67.9% predicted) (Table 2). Five months postoperatively, he returned to 
a normal life without oxygen inhalation and is able to perform daily activities. 
 
Discussion 
 After bone marrow transplantation, if the patient has received marrow from a compatible but dissimilar 
ABO type, serum antibodies will not agree with red cell antigens. The present pediatric patient, who was 
originally type AB received type O marrow, had circulating type O red cells but produced no anti-A/B 
antibody in the serum at the time of lung transplantation. According to ABO testing of red cells, recipient 
(type O)-donors (B and AB) ABO type matching was incompatible, however, since the recipient had no 
anti-A/B antibody in serum, we could perform this surgical procedure with ABO incompatible donors. 
Other possible hematological change that may occur in the recipient after lung transplantation was 
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carefully discussed.  Theoretically, the lymphocytes derived from type B lung donor might produce anti-
A antibodies in the recipient, and not only attack the recipient’s other organs which were originally type 
AB, but also attack contralateral type AB donor lung. However, there was only transient weak detection 
of anti-A antibodies and no AMR occurred postoperatively. 
 Recently, many cases of ABO-incompatible organ transplantation, especially kidney and liver 
transplantation have been performed to overcome donor organ shortage. Japanese groups reported 
excellent patient and graft survival of ABO-incompatible kidney transplantation using regimens including 
plasmapheresis, immunosuppression, immunoabsorption and splenectomy, which showed a similar 
outcomes to those of ABO-compatible donor transplants2, 3. However, intentional ABO-incompatible 
lung transplant was reported in only one case. 4  Pierson et al. reported 42 cases (0.4%) of accidental 
ABO-incompatible lung transplants among 9,804 primary lung transplants according to the database of 
the Organ Procurement and Transplant Network in the United States 5 and the outcome was acceptable 
compared with those of ABO-compatible lung transplants when the intensive therapy described above has 
been used. 
 Although the present case showed a unique blood type background because of prior bone marrow 
transplantation, to our knowledge, this case represents the first successful living-donor lobar lung 
transplantation from ABO-incompatible donors. Although the short-term outcome was satisfactory, long-
term follow-up is needed to assess whether this procedure is ultimately justified. 
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Table 1. The serological analysis of anti-A and anti-B antibody in the recipient 
 
 
POD after transplant  pre 7 12 19 26 54 82 
 
Aggregation to type A RBC* 0 w+** 0 w+ w+ 0 0 
Aggregation to type B RBC 0 0 0 0 0 0 0 
 
* Red blood cells, ** very weak aggregation 
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Table 2. The time trend of pulmonary function test in the recipient 
 
 
POD after transplant  pre  82  188 
 
Height (cm)   127.0  127.4  128.0 
Body Weight (kg)  24.0  25.0  28.0 
 
VC (L)    0.72  1.62  1.61 
FVC (L)   0.72  1.53  1.60 
FEV1.0 (L)   0.27  1.12  1.09 
 
 
 
 
